OBJECTIVES AND DEPLOYMENT OF THE FRANCE 2030 RECOVERY PLAN
Learning from the health crisis: repairing the past
The Covid-19 epidemic showed strategic importance of the healthcare industries sector and the decisive aspect of French sovereignty in healthcare. A few figures illustrate the need for secure access drugs and medical devices.
- Balance of trade : in pharmaceuticals/medical devices, France produces 51% of its products in France. And 49% outside France. By way of comparison, Germany produces 58% on its territory, and Italy 64%.
- Access to medicines and medical devices : 17% have a very high supply vulnerability index and 23% a medium vulnerability index. That's 40% of products that are vulnerable in our consumption.
Furthermore, according to The Shift ProjectThese imports of medicines and medical devices account for 33% of the healthcare sector's greenhouse gas emissions. It is vital to build a solid, innovative industrial base in the healthcare sector. The challenge is to commit France to a reindustrialization and relocation of production of these products.
The 2030 healthcare innovation plan: preparing for the future
The "Innovation Santé 2030" plan 7.5 billion euros to make France the most innovative and sovereign healthcare nation in Europe. In concrete terms, it's a plan to stimulate public spending - or a Keynesian investment plan.
It comprises 7 strategic areas:
Strengthening biomedical research
With theemergence of IHU and new clustersthe strengthening of training and thehosting researchers.
Creation of a health innovation agency
To create a pulse and a strategic innovation management (the contours of which have yet to be defined, as many initiatives already exist).
Providing a predictable, coherent economic framework conducive to business opportunities
Purchasing policy of healthcare establishments plays an essential role in guaranteeing security of supply and enabling the development of small/medium-sized businesses and start-ups. To be able to anticipate and follow the regulation of the sector, companies need visibility.
Supporting forward-looking sectors in the healthcare industry
Innovative therapies, biotherapies, digital health... for 2.5 million euros.
Fair access to healthcare
For patients and provide a framework for accelerated market access for innovations telehealth, innovative procedures - including non-nomenclature procedures and treatments.
Supporting the industrialization of healthcare products
To accompany company growth3.5 billion in BPI funds.
Strengthening clinical trials in France
National sovereignty as a strategic and commercial opportunity
French strategic and vulnerable products represent 100 billion euros of imports. 35% can be relocated to France because they come from iso-competitive geographies.
The top 4 strategic and vulnerable products include :
Medical devices
Prostheses, joints and artificial organs, optics... represent 5 billion euros of imports (in terms of sales), with a relocation potential of 35% (or 1.8 billion euros in added value).
Medical equipment
Medical equipment (therapeutic, such as respirators, and diagnostic, such as radiology) accounts for 2 billion euros of imports (in terms of sales), with a 30% relocation potential (equivalent to 630 million euros of added value).
Hormones
Hormones represent a total of 2.6 billion euros of imports (in terms of sales), with a relocation potential of 50% (or 1.3 billion euros in added value).
Antibiotics and antibacterials
They represent 1.2 billion euros of imports (in terms of sales), with a 30% relocation potential (i.e. 350 million euros of added value).
It's a real dynamic that's taking shape, and a business opportunity for French and international players, both public and private.
TOWARDS A TRANSFORMATION OF THE HEALTHCARE SYSTEM
The essential role of collective initiatives
The numerous calls for projects are aimed at strengthen existing bridges between collective initiatives in basic research, applied research and marketing. Today, an IHU that does not take the industrial environment into account is less likely to succeed.
A BioCluster focused solely on industrial players does not meet these expectations. Calls for projects and major policies now require all players to work together to develop collective projects.
At the same time, numerous local initiatives are taking shape. For example, Art 51s, initiatives linked to all the structures that help accelerate projects: PSC, Digital Pharma Lab, HHC... These collective initiatives are essential. They help to build a common culture around healthcare, but also to foster key innovations.
These collective initiatives are essential. They help to build a common culture around healthcare, but also to foster key innovations.
Increasing the skills of local authorities
The sector's lack of appeal is weighing on healthcare providers, particularly hospitals and private practitioners. The situation seems to be at a standstill: despite rising salaries and multiple revisions to hospital governance, many professionals (in operating theatres, EHPADs, etc.) are still missing in action.
Banking on the development of differentiated territorial logics could well be the key to the problem. Local authorities, having taken a liking to their commitment to healthcare players during the Covid-19 crisis, are increasingly taking up these issues. The regions, départements and even communes are taking numerous initiatives (financing housing, helping people to set up in business, prevention initiatives, etc.). They are growing in competence, which augurs well for a strengthening of their role in the future.
Nevertheless, it should be remembered that it took over 10 years to actually implement activity-based pricing (T2A). We can therefore assume that changing the system will take time...
